Abstract:To study the therapeutic effect of Zanthoxylum on glucose and lipid metabolism disorder in type 2 diabetes mellitus (T2DM) mice, the mouse model of T2DM was established by using high fat and high sugar feed and streptozotocin (STZ). The mice were divided into blank group, model group, high dose of Zanthoxydim (0.8 mg/kg bw), low dose of Zanthoxydim (0.4 mg/kg bw) and positive control (100 mg/kg bw) groups, with 10 mice in each group. The feed intake, water intake, body weight and fasting blood glucose of mice were measured during the experiment. Glucose tolerance (total cholesterol, TC), triglyceride (TG), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C) and malondialdehyde (MDA) in serum and liver of mice were measured, and the morphological changes of mouse liver tissues in each group was observed by HE staining after 28 days of intragastric administration. The results showed that Zanthoxylum can significantly (p<0.05) reduce the contents of TG, TC, LDL-C and MDA in serum, and significantly (p<0.05) increase the content of HDL-C; compared with the model group, the contents of TG, TC and MDA in the liver of the high-dose group decreased significantly (p<0.05) by 28.31%, 43.56% and 52.14%, respectively, which were equivalent to those of the positive control group. And the morphological test results showed that after 28 days of treatment, compared with the model group, the degree of liver tissue damage in the high and low dose groups was significantly reduced. The results indicated that Zanthoxylum can improve glucose and lipid metabolism and stress response in T2DM mice.
